NCT04267848 2026-04-15
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06498635 2026-04-14
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT05812807 2026-04-07
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06401330 2026-03-05
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Children's Oncology Group
Phase 3 Recruiting
NCT06647953 2026-02-24
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Children's Oncology Group
Phase 3 Recruiting
NCT03180268 2026-01-14
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NRG Oncology
Phase 3 Recruiting
NCT05717166 2025-12-31
SABR-SYNC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT02355379 2024-07-08
ADAGE
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT06313567 2024-07-08
Metronomic Capecitabine in Stage III Gastric Cancer
Fudan University
Phase 3 Recruiting